Abstract：Objective: To investigate the effects of liraglutide on endothelial function and immune function in elderly patients with type 2 diabetes mellitus complicated with hyperlipidemia. Methods: 86 elderly patients with diabetes mellitus complicated with hyperlipidemia were enrolled in the general practice department of the hospital from January 2018 to February 2019. They were randomly divided into the control group and the liraglutide group, with 43 cases in each group. The control group was treated with metformin treatment. The liraglutide group was given subcutaneous injection of liraglutide. The two groups were observed for 2 months. Blood glucose and blood lipids were measured before and after the study [blood sugar (FBG), postprandial 2 h blood glucose (2 h PG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), low density lipid) Protein (LDL-C), high-density lipoprotein (HDL-C) and body mass index (BMI), comparing endothelial function indicators [ET-1 and NO] and immune function [hypersensitive C-reactive protein (hs-CRP), IgM and IgG]. Results: After treatment with liraglutide group, FBG, 2 h PG, TC and TG were lower than those in the control group (P<0.05). After treatment with liraglutide group, HbA1c, LDL-C and HDL-C were compared with the control group. There was no significant difference between BMI and BMI (P>0.05). After treatment with liraglutide, ET-1 was significantly lower than that before treatment (P<0.01). There was no significant difference in NO after treatment with liraglutide group (P>0.05). After treatment with liraglutide group, ET The level of -1 was lower than that of the control group (P<0.05), and the level of NO was higher in the liraglutide group than in the control group (P<0.05). The hs-CRP was decreased after treatment with the liraglutide group compared with the control group, while the IgG was higher than the control group (P<0.05). Conclusion: The effect of lilalutide on the elderly type 2 diabetes mellitus with hyperlipidemia is more obvious. It can alleviate the damage of endothelial function, increase the immune function and reduce the inflammatory response.
常盼, 张晓萌, 王西辉, 李静, 吴娟, 于军. 利拉鲁肽对老年2型糖尿病合并高脂血症患者内皮功能和免疫功能的影响[J]. 河北医学, 2020, 26(3): 433-436.
CHANG Pan, ZHANG Xiaomeng, WANG Xihui, et al. Effects of Liraglutide on Endothelial Function and Immune Function in Elderly Patients with Type 2 Diabetes Mellitus Complicated with Hyperlipidemia. HeBei Med, 2020, 26(3): 433-436.
[1] Zhou X,Zhang W,Liu X,et al. Interrelationship between diabetes and periodontitis: role of hyperlipidemia[J]. Arch Oral Biol,2015,60(4):667~674. [2] 何柳平,楚罗湘,马粉娜.普伐他汀治疗对糖尿病并发高脂血症患者血脂、超敏C反应蛋白和血小板活化的影响[J].内科,2016,11(4):540~542. [3] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes[J]. N Engl J Med,2016,375(4):311~322. [4] 中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292~344. [5] 诸骏仁,高润霖,赵水平,等.中国成人血脂异常防治指南(2016年修订版)[J].中国循环杂志,2016,31(10):937~953. [6] 李秀丹,石立力,姜晓艳.血管平滑肌细胞自噬与糖尿病动脉粥样硬化关系的研究进展[J].临床心血管病杂志,2019,35(1):97~100. [7] 胡希红,骆丽,鲁燕.老年糖尿病患者餐后三酰甘油升高对血管内皮功能的影响[J].中国药物经济学,2015,10(12):86~88. [8] Ajmal MR,Yaccha M,Malik MA,et al.Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients ofcardiovascular diseases and its association with hs~CRP and TNF-α[J]. Indian Heart,2014,66(6):574~579. [9] Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors[J]. Diabetes Obes Metab,2016,18(3):203~216. [10] Bouchi R,Nakano Y,Fukuda T,et al. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis,albuminuria,and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial[J].Endocr,2017,64(3):269~281. [11] 陈晨, 王芳,张庆富.利拉鲁肽联合胰岛素治疗2型糖尿病患者临床效果及对血脂指标影响观察[J].中国社区医师,2019,35(9):14~16.
2020, Vol. 26 
冀公网安备13080202000677号